OMNITIDES
"OMNITIDES" is a word and design mark owned by Crystal Bioscience, Inc., filed at the USPTO on October 6, 2026. It is under examination and covers classes 1, 5, 40 and 42.
- Status
- Under examination
- Since October 6, 2026
- Filed
- October 6, 2026
- Registered
- Not yet
- Expires
- Not recorded
- Application no.
- 50146214
- Registration no.
- Not yet
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word and design
- 4 classes
Who owns OMNITIDES
The owner and representative on file with the office.
Owner
Crystal Bioscience, Inc.
Emeryville, United States
Representative
Francis P. Cislak
Barnes & Thornburg LLP
What the mark covers
The products and services OMNITIDES is filed for, grouped by Nice class.
synthesized peptides for scientific and research use; for research purposes, excluding those for medical or veterinary use; proteins and synthesized peptides used in the research, product development, and manufacture of pharmaceuticals; chemical reagents for use in evaluating genetic material, namely, the detection, measurement and identification of genetic materials and their compounds, excluding those for medical and veterinary use; biological tissue, namely, animal tissue for use in scientific and medical research; cells for scientific and research use; stem cells for scientific and research use; synthesized peptides for scientific and research use, the amino acid sequences of which were identified through or derived from naturally optimized, in vivo generated biological processes; synthesized peptides for scientific and research use, based on peptide sequences originally generated and optimized in vivo
synthesized peptides for medical use, namely, for the treatment of viral, respiratory, autoimmune, immune, inflammatory, dermatological, endocrine, heptalogical, metabolic, infectious diseases and disorders, cancer, and pain; biological reagents for medical use; chemical reagents for medical use, namely, for the detection, measurement and identification of genetic materials; biological tissue cultures, namely, animal tissue cultures for medical purposes; radiopharmaceutical compositions for medical diagnostic or therapeutic use, namely, diagnostic radiopharmaceutical preparations and radiopharmaceuticals for the diagnosis or treatment of cancer, cardiovascular disease, lung disease, thyroid disease, bone disease, brain disease, and bodily tissue disease; synthesized peptides for use in drug discovery of pharmaceuticals for the treatment of viral, respiratory, autoimmune, immune, inflammatory, dermatological, endocrine, heptalogical, metabolic, infectious diseases and disorders, cancer, and pain; chemical preparations for use in drug discovery for the treatment of viral, respiratory, autoimmune, immune, inflammatory, dermatological, endocrine, heptalogical, metabolic, infectious diseases and disorders, cancer, and pain; pharmaceutical preparations for use in the treatment of medical conditions, namely, suppressing tumors; diagnostic preparations for medical purposes; pharmaceutical preparations in the nature of synthesized peptides for use in drug discovery and pharmaceuticals for the treatment of medical purposes; synthesized proteins and chemical preparations for use in drug discovery and pharmaceuticals for the treatment of viral, respiratory, autoimmune, immune, inflammatory, dermatological, endocrine, heptalogical, metabolic, infectious diseases and disorders, cancer, and pain
manufacture of synthetic peptides to the order and specification of others; peptide synthesis for others, namely, manufacture of synthetic peptides to the order and specification of others; discovery-to-synthesis of synthetic peptides
scientific research services in the field of the analysis and synthesis of peptides; scientific research services in the field of the analysis and synthesis of proteins; quality control of peptides used in drug development; advice on quality control of peptides used in drug development; scientific research and development; scientific research and development in the field of immunization; generation, analysis and synthesis workflows for peptides
What has happened so far
Steps recorded by the USPTO, newest first.
- Application filing receipt mailed
- New application entered
About OMNITIDES
Who owns the trademark "OMNITIDES"?
The USPTO trademark "OMNITIDES" (application 50146214) is owned by Crystal Bioscience, Inc.
What is the status of "OMNITIDES"?
Its status at the USPTO is: under examination.
Get this data via the API
Everything on this page comes from the Signa API. Pull OMNITIDES and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_01a11679-a87b-773a-b932-bb1fef8fc5fa
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_01a11679-a87b-773a-b932-bb1fef8fc5fa",
"object": "trademark",
"mark_text": "OMNITIDES",
"status": {
"primary": "pending",
"stage": "examining"
},
"office_code": "US",
"application_number": "50146214",
"filing_date": "2026-10-06",
"nice_classes": [
1,
5,
40,
42
],
"owners": [
{
"name": "Crystal Bioscience, Inc.",
"entity_id": null
}
]
}